Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis

Journal of Clinical Apheresis
Ralf SpitthöverReinhard Klingel

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with monoclonal antibodies has complemented the armamentarium of lipid-lowering therapy (LLT) before the final step of commencing chronic lipoprotein apheresis (LA). Data are scarce on patients who, after escalation of LLT with PCSK9 antibodies, have commenced chronic LA or PCSK9 antibody treatment during ongoing long-term LA. In this study, a cohort of 110 patients with established atherosclerotic cardiovascular disease (ASCVD) due to hypercholesterolemia or concomitant lipoprotein(a)-hyperlipoproteinemia, who received PCSK9 antibodies for the first time during routine care, were consecutively identified. Mean LDL-C concentration prior to initiation of LA or PCSK9 antibody treatment was 5.3 ± 2.6 mmol/L (205 ± 102 mg/dL). Due to established ASCVD, the risk-adjusted LDL-C target value was <1.8 mmol/L (<70 mg/dL) in all patients. Use of PCSK9 antibodies increased the proportion of patients attaining the LDL-C target concentration by 41.8% overall. Treatment emergent adverse events (TEAE) associated with PCSK9 antibody medication were reported in 35 patients (31.8%). Discontinuation of PCSK9 antibody therapy due to TEAEs occurred in 25 patients (22.7%). Finally, 55....Continue Reading

References

Mar 29, 2008·Atherosclerosis·G R Thompson, UNKNOWN HEART-UK LDL Apheresis Working Group
Jul 11, 2009·Atherosclerosis·Gilbert R ThompsonS Watkins
Oct 23, 2010·European Heart Journal·Børge G NordestgaardUNKNOWN European Atherosclerosis Society Consensus Panel
Dec 1, 2012·Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance·Jochen M GrimmTobias Saam
Jan 15, 2014·International Journal of Cardiology·Gerald F WattsJohn J P Kastelein
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Dec 22, 2015·Journal of Clinical Lipidology·Patrick M MoriartyUNKNOWN ODYSSEY ALTERNATIVE Investigators
Apr 4, 2016·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN GAUSS-3 Investigators
Jun 2, 2016·The Lancet. Diabetes & Endocrinology·Raul D SantosUNKNOWN International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
Jul 16, 2016·Arteriosclerosis, Thrombosis, and Vascular Biology·Eberhard RoeselerUNKNOWN Pro(a)LiFe-Study Group
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Dec 14, 2016·The New England Journal of Medicine·Rachel E ShermanRobert M Califf
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Nov 4, 2017·Atherosclerosis. Supplements·V J J SchettlerUNKNOWN Scientific Board of GLAR for the German Apheresis Working Group
Dec 20, 2017·Atherosclerosis·Robert M StoekenbroekG Kees Hovingh
Feb 6, 2018·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Knut Tore LappegårdAnders Hovland
May 16, 2018·Clinical Chemistry·Michel R LangloisUNKNOWN European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Join
Nov 8, 2018·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN ODYSSEY OUTCOMES Committees and Investigators

❮ Previous
Next ❯

Citations

Sep 19, 2020·Current Atherosclerosis Reports·Sergei N PokrovskyMarat V Ezhov
Nov 27, 2019·European Journal of Preventive Cardiology·Francesco SbranaTiziana Sampietro
Dec 12, 2019·Frontiers in Endocrinology·Yu HuRong Yuan

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.